We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A federal judge awarded Fresenius a preliminary injunction that blocks Fera Pharmaceuticals from marketing a levothyroxine sodium generic for the treatment of an underactive thyroid. Read More
Thirty-five states have filed an antitrust lawsuit against Indivior, alleging the company engaged in anticompetitive practices to block generics and inflate the price of the company’s opioid addiction treatment Suboxone. Read More
The U.S. Court of Appeals for the Federal Circuit affirmed the validity of Abbott’s protein-binding patent, handing yet another victory to the company in a decades-long dispute with Yeda Research and Development. Read More
California Gov. Jerry Brown (D) signed into law a bill that would allow companies, nonprofits and government agencies to purchase and maintain Mylan’s EpiPen for emergency use, while criticizing the company for the hiking the price of the allergy treatment. Read More
The Senate Finance Committee and West Virginia’s attorney general are requesting information on the rebates Mylan paid to Medicaid for its allergy treatment EpiPen, a day ahead of a hearing on the price of the combination product. Read More
A federal judge signed off on a $486 million settlement between Pfizer and the company’s shareholders to end a long-standing class action suit alleging the company misrepresented the cardiovascular risks of its analgesics Celebrex and Bextra. Read More